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1ORIGINAL ARTICLES
From the Society for Vascular Surgery
Every year, the Society for Vascular Surgery
bestows a singular honor on one of its members, its
Presidency. Fifty-one of my predecessors have ex-
pressed their gratitude for this in various ways, but
I’m sure all felt as I do: that to be elected to this office
by one’s peers is indeed a supreme recognition. And
for me, it resulted in one of life’s very high moments.
I know no other way to convey this than to sincerely
say, thank you; thank you for this honor, privilege,
and opportunity to have served you.
The title of this address reflects my acute aware-
ness that we are in a time of great transition. “Legend,
leadership, legacy” is translatable to the past, the pre-
sent, and the future, but with specific implications.
First, we must not, in this chaotic time of change,
forget that we are the custodians of the welfare of our
patients, who are afflicted with the devastating illness
of vascular disease. Second, we must not succumb to
the tremendous pressures to change until and unless
we really know that it is the right thing to do.
All this is in the presence of enormous external
forces largely out of our control. Our work is being
devalued, our creativity is being strangled, our finances
are being eroded, and our turf is under attack. Our
very lives are being forced to change in an era in which
everything is happening much too fast, and there is no
time for reflection.
But reflect we must. We must take a deep breath and
consider where we’ve been, where we are, and where we
are going. Legend, leadership, and legacy—we must
draw on these concepts to develop a steady and correct
course. Thus, this address will be historical, philosophi-
cal, rhetorical, and, lastly, somewhat personal.
Legend is the record of the past, what worked,
and who did it. The results are the major contribu-
tions to our field. Legacy is what happens if what is
done turns out to be the right thing, thereby result-
ing in future success. Leadership is what is needed to
make the right decisions to achieve that success.
Leaders must possess a blend of skills, including
boldness, wisdom, and judgment. Leadership is the
linkage of the past to the future—from the legend to
the legacy. It is this linkage that is crucial to the
preservation and nurturing of our collective creativ-
ity and identity—issues to which I will return later.
As an example of legend, I have chosen a person
whose contributions began 100 years ago, contin-
ued through the 1930s, and took 20 to 30 more
years for their full impact to be realized, Alexis
Carrel (Fig 1). Through a detailed review of the life,
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Fig 1. Alexis Carrel, circa 1930.
the work, and the creativity of Carrel, I hope you
will gain insight on the legend-to-legacy issue.
Alexis Carrel was born outside Lyons, France, in
1873 and died in Paris in 1944. No previous presi-
dent spent much time on Carrel, and I always won-
dered why. It was not until 1974 that a biography of
him was written in English, by Sterling Edwards.
Edwards must also have wondered why no one had
spent much time on Carrel. With this excellent book,
I started my research. Carrel was a creative genius,
with all the assets and all the faults. He was the first
scientist working in North America to win a Nobel
Prize in physiology and medicine, in 1912 for the
work about which we all know. But that work is just
an instant in the life of a rather extraordinary person.
I first became aware of Carrel when I was in the
Navy at the Naval Medical Research Institute’s Tissue
Bank, and Carrel’s work on organ culture was being
reproduced and extended there with the consultation
of Charles Lindbergh, who had worked with Carrel
30 years before. The general, as he was called, used to
come every several months, and from him I learned of
Carrel, Carrel’s creative genius, and something about
the creative process itself. I don’t know why, but
almost immediately after I realized I had to write this
address, I knew Carrel would be part of it.
Carrel was an experimental surgeon and never
practiced clinical surgery, although he had taken
clinical training in Lyons. He became interested in
the problems of vascular anastomosis in 1894, after
the president of France died in Lyons of hemorrhage
from a lacerating stab wound of the portal vein,
which the surgeons did not know how to repair.
As an intern in 1896, Carrel began the anasto-
mosis work for which he gained considerable public
notoriety, even at that early stage. He failed the final
examination for staff appointment, called “the
course,” for the first time in 1901 and then again in
1902. It was made clear to him that he was never
going to pass “the course,” so, frustrated, he chose
to emigrate to North America in 1904. He thought
he would become a rancher.
Fate rescued Carrel, however, when Karl Beck
invited him to Chicago, where Carrel continued his
vascular surgery research in collaboration with
Charles Guthrie at the University of Chicago. He
was only there for about 2 years, but they were very
productive years. He perfected end-to-end and then
end-to-side anastomosis for arteries, using running
sutures with the triangulation technique. Fine nee-
dles, fine sutures of silk coated with petrolatum to
minimize vascular wall injury (remember waxing
multifilament sutures?), a “no touch” technique,
and impeccable asepsis were all part of the successful
formula. From these, he moved to veno-arterial
anastomoses, then to venous interposition grafts,
and then to vein patches to widen primary closure.
The Carrel button was the prelude to organ trans-
plantation, and he achieved both autografts and allo-
grafts of thyroid, kidney, heart, and even limbs. All
these achievements received great notoriety in the
lay press. Some have said that it was Guthrie who
should have gotten the credit. This is mistaken, as
the subsequent careers of both Guthrie and Carrel
have amply demonstrated. This was Carrel’s work,
which began in France and earned him the Nobel
Prize in 1912, having been nominated by Karl Beck.
The rest of Carrel’s career was spent at the newly
endowed Rockefeller Institute for Medical Research
in New York, where he became one of the first fel-
lows in 1906. His recruitment there followed a most
remarkable lecture, given at Johns Hopkins, that
summarized his scientific accomplishments to that
point. At the Rockefeller Institute, his research
interests began to follow a very logical sequence—a
process seen in many great creative geniuses. From
his early work, he progressed to cell culture, and he
became one of the founders of that field. Space does
not permit a detailed examination of that work and
its immense general importance to the tissue culture
field. However, beginning in 1908, he perfected the
methods of studying warm-blooded mammalian
cells in culture to study wound healing, diseases such
as cancer, and tissue preservation for later transplan-
tation. Some cells from a well-publicized experiment
on a chick heart were kept in continuous culture for
30 years—probably helped along with cell “refresh-
ment” by zealous assistants, but, nevertheless, a real
accomplishment.
From cell culture, he moved to organ culture,
and it was the organ culture work that resulted in his
collaboration with Lindbergh. In 1930, Lindbergh
sought out Carrel to develop a method to stop and
repair the heart, because Lindbergh’s sister-in-law
had rheumatic heart disease. The Carrel-Lindbergh
perfusion apparatus was developed to be an artificial
heart, but it was used in the study of perfused thy-
roid and hearts with successful preservation up to 3
weeks and in studies of organ function.
Carrel’s research productivity essentially ended
in 1938 with the publication of a book, The Culture
of Organs, coauthored with Charles Lindbergh.
However, Carrel’s creativity is inspiring in its pro-
gression from the elemental anastomosis work to tis-
sue culture, to organ culture, and then to the final
step. One only needs to review his rich bibliography
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to see where his work was going—to studies of
humankind itself. That comes later, but the associat-
ed contributions along the way are enormous.
Carrel’s anastomotic work led to the first blood
transfusion in New York City. The baby of a promi-
nent surgeon with melena neonatorum was treated
by Carrel, who anastomosed the father’s radial
artery to the baby’s popliteal vein. All this was done
on the dining room table. This took place before
blood typing, but fortunately the 2 matched. The
baby and the father’s hand both survived.
The tissue culture work with its demands for
asepsis led to the treatment of wounds in World War
I with the Carrel-Dakin method, using Dakin’s solu-
tion, which is still in occasional use today. During
the war, Carrel established a hospital in France ded-
icated to the research and treatment of war wounds,
and later he developed training methods for military
surgeons in a demonstration hospital back at the
Rockefeller Institute.
He also explored the possibilities of blood sub-
stitutes, the importance of maintaining normal body
temperature during surgery, hypothermia for
ischemic organ protection during surgical proce-
dures, and endotracheal respiratory support for tho-
racic procedures.
The organ culture work was a prelude to extra-
corporeal circulation, decades before it became a
reality. And Carrel’s notable work on the preserva-
tion of tissue led to the era of arterial homografts
and venous autografts for arterial reconstruction.
Despite his strenuous objections, Carrel was
forced to retire from the Rockefeller Institute at the
age of 65 in 1939, a politically motivated move that
left him bitter. What particularly hurt him was that his
Department of Experimental Surgery was closed.
Carrel had become quite unpopular because of his
perceived arrogance and aloofness. Part of this was a
problem with language. Although he wrote in English
beautifully, he never perfected the spoken word.
Furthermore, his failure to become an American citi-
zen, despite his having received so much financial and
other support in America, rankled his superiors. In
1935, Carrel wrote a book for the lay readership titled
Man the Unknown, which reflected his views, as a sci-
entist, on life and the future of humankind. It became
a best seller. It is easy to see, even from the table of
contents, where he was going (Fig 2). This path was
to be his ultimate undoing.
After his retirement in 1939, Carrel returned to
France. While working on Man the Unknown, he got
the idea that his final work should be in the creation
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Fig 2. Title page and table of contents from Man the Unknown.
of an institute where all the problems of humankind
could be scientifically and intellectually pursued and
maybe solved. Unsuccessful in America, he was able
to establish this institute, the Institute for the Study
of Human Problems, in France in 1941. This was to
be the culmination of his life’s work, all headed to
the betterment of humankind. It started out all
right, but immediately ran into political trouble. By
then, Carrel was having heart problems, and he died
at age 71 in 1944. His institute was closed soon
thereafter. Today Carrel’s place in history in France
is still quite controversial, and his memory in the
United States has largely shrunk to the contributions
related to vascular anastomoses.
Fifty years after his death, this man who achieved
so much seems so under recognized. Why? One rea-
son I focused on Alexis Carrel in this address is that
I believe his significant legacy to vascular surgery
deserves a more complete chronicle in the archives
of the Society for Vascular Surgery. Another reason
is that I wanted to use Carrel as a success/failure
example in the legend-to-legacy assimilation.
There is no question about Carrel’s legend. And
there is no question he left an important legacy. Why
isn’t this legacy more apparent? At the risk of being
posthumously critical, I say that Carrel failed himself
and humankind by making some unfortunate leader-
ship decisions, in both boldness and judgment. This is
personal speculation, but I believe Carrel’s leadership
failure caused his legacy to fall short. This was the fault
of genius, perhaps, but true anyway. I have selected
two examples from a number of examples that support
my view, one early in his life and one at the end.
I mentioned he never passed “the course,” or the
examination for a staff position in Lyons and, hence,
emigrated to the United States. One reason for this is
that, after a visit to the Shrine at Lourdes in 1903, he
was led to believe he would never pass. Lourdes is the
place where miracles happen, and he observed one.
The story is beautifully told in a fictional, but thinly
disguised autobiographical, work written by Carrel
and published after his death, A Voyage to Lourdes. It is
wonderful reading. In it, Louis Lerrac (Carrel spelled
backwards) is a substitute physician for a pilgrimage to
Lourdes. On the way, he encounters a young woman
seemingly near death from what Carrel and others
were quite sure was tuberculous peritonitis. Carrel
observes that within hours after topical application of
the water from the grotto, the woman miraculously
begins to improve and ultimately recovers. She sur-
vived until 1938, when she died of natural causes. Was
this a miracle or not? Carrel was almost convinced, but
not quite. This baffled Carrel as a scientist and
intrigued him as a mystic, but he couldn’t reconcile it.
His mysticism is out of the scope of this address, but
his decision isn’t. He hedged. His scientific work had
already gained him considerable notoriety, so he spoke
of it to the press. He wouldn’t totally acclaim it as a
miracle, and this made the church unhappy. He
wouldn’t declaim it as a mere hysterical conversion, so
the medical establishment was also unhappy. This led
to his ostracism. This was leadership failure as evi-
denced by lack of decisiveness or boldness and by lack
of judgment by not just remaining silent in indecision.
The result was his emigration, but fortunately, his
career progressed.
It was different at the end of his life. All his scien-
tific work was leading in one seemingly logical direc-
tion: the betterment of humankind or, from the
French, the perfectibility of humankind; from tissue
culture, to organ culture, to human culture or eugen-
ics. This was not a great choice in France in 1941.
This is what the Institute of Man was about—or so it
was interpreted. That’s why the free French or Vichy
government financially supported it, and that’s why
the Nazi German regime allowed it in occupied
France in Paris. His close friendship with Lindbergh,
who was widely regarded to have German sympathies,
also didn’t help. This led to the accusation and belief
that Carrel was a Nazi collaborator. The historic
record shows that this is probably not true, but it
killed Carrel’s efforts, probably helped kill him, and
insidiously diminished his reputation and, thereby, his
real legacy.
So, what has this got to do with today? Actually, a
great deal. With an understanding of legend, both
people and events, and with an understanding of lega-
cy and the reasons for it, we can more carefully con-
sider the process of creating it. And that is leadership.
Leadership has a broader scope now, but it still
comes down to individuals taking the responsibility
of making decisions of importance to themselves and
others. If the leadership fails, the legend may persist,
but the legacy is diminished. This is what happened
to Alexis Carrel.
The point, and the real message of this address,
is our legacy—what we do today that will define our
future. Certainly, we do have future legends in our
field; many are in this room. History will be the
judge of that.
However, in these troubled times, we need an
intense focus on creating our legacy. And for this, we
need lots of leadership, and we need it now. Boldness
and judgment, somewhat lacking in my selection for
legend, are both needed to face today’s issues. Of the
many issues, I will focus on two: creativity and identity.
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We need leadership to better cultivate, stimulate,
and support the creative process in vascular sur-
geons. Our young surgeons, in particular, are being
stifled by economic and other pressures, driving
them toward practical and easily identifiable produc-
tivity and away from fundamental creativity. This is
greatly related to finance and financial support. One
might argue that there is plenty of innovation going
on. Certainly, endoluminal therapies are the stuff of
Carrel’s genius. However, this is mainly industry-
based product development and not what I’m talk-
ing about.
Basic research productivity is good, but needs
substantial nurturing in the environment of shrink-
ing research support. Too much research funding is
directed to PhDs who do research full time, and not
enough funding is directed to surgeon scientists who
not only understand the clinical problems needing
research, but also how to research them—bedside to
bench and back again. Our superb creation, the
Lifeline Foundation, is a great step forward, but
only a scant 14% of our membership support it
financially. How are we possibly going to be able to
convince others to support it at this rate? Moreover,
please think about this: Without the philanthropic
support of Rockefeller to the institute that bears his
name, Carrel’s work may never have progressed.
However, there’s more to this than money. We
must find ways to depressurize the academic surgery
atmosphere and reward creativity that doesn’t earn
money, thereby allowing the creative spirit of our
young and not-so-young surgeon investigators to
prosper and their creative sap to flow. Research is
vital to our legacy, because it stimulates both inves-
tigator and noninvestigator, resulting in an aura of
inquisitiveness and motivation to search for better
ways to do things. Without research, vascular
surgery is in danger of becoming an intellectual
desert, leaving us as mere technicians. Leadership
today can and must keep us from that arid legacy.
Another great challenge needing leadership is in
the area of identity, the definition of our specialty
for the near and longer-term future. This will be the
essence of the legacy of today’s leadership. In the
midst of this period of turbulent transition, I believe
that we have an identity problem. We think we
know who we are, but do we really? Others most
certainly don’t.
Our relationship with the American Board of
Surgery (ABS) is a very good example of this and
why it is so important for us to get this settled cor-
rectly now. This issue is not about board certification
per se, but about certification clarifying our identity.
The problem is this: Vascular surgeons currently
do not have the necessary authority within the ABS
to shape the nature of our field—our identity, if you
will. In spite of continuing and sincere efforts, we
weren’t making much progress with the ABS, which
until now has considered us as general surgeons with
some added exposure and experience with vascular
problems. In their view, because vascular surgery is a
primary component of general surgery training, any-
one finishing a 5-year general surgery residency is
qualified to do vascular surgery. Maybe this was true
once, but it’s preposterous now. Anyone starting a
practice today and intending to do a significant
amount of vascular surgery should have taken the
specialized training and received certification that
they have successfully completed it. So what’s the
big deal? We’ve had certification for 15 years. The
problem has been that what defines being qualified
for certification has not generally been under the
authority of recognizable vascular surgeons. This is
not to demean our earlier and current representa-
tives to the ABS. They merely were not given the
tools to conduct the business of vascular surgery,
and that’s what needs to change.
In fact, vascular surgery qualifies in every way to
be a primary independent board. And so, in frustra-
tion, we formed our own board, the American
Board of Vascular Surgery, in 1996. However, the
authority to issue certificates must be gained from
the American Board of Medical Specialists, and that
is not a quick or straightforward process. Nor is
there guaranteed success. In the meantime, in 1996,
we also identified what the ABS would need to do
for us to get the job done with them. Not wishing
to see further fragmentation of surgery unless
absolutely necessary, all agreed that a satisfactory
solution within the ABS would be preferable, there-
by keeping surgery whole. We have other pressing,
nonsurgeon-related problems with which we need
to contend. Because the ABS has never been partic-
ularly receptive to change, no one thought they
could or would change enough to allow this to hap-
pen. But, in fact, the ABS did respond with substan-
tial change in recognition of current realities.
In January 1998, the ABS voted to create a sub-
specialty board in vascular surgery under their aegis
and invited us to join in this effort. The ABS Sub-
Board for Vascular Surgery is to be made up of vas-
cular surgeons we will select. Authority for the doing
of the business of vascular surgery is to be delegated
to our sub-board.
Despite this, we’re not sure whether the ABS
really will do what it recently has promised. And
JOURNAL OF VASCULAR SURGERY
Volume 29, Number 1 Abbott 5
even if they do, will it be enough? I don’t know, but
it is my personal conviction that the only way we will
ever find out is to try it. Considerable skepticism
exists as to whether the ABS can really “give”
enough to make this work. I share that skepticism,
but I also believe we need to try this now. We ulti-
mately will have to make the first step based on good
faith, which is a bold leadership step. And what’s the
downside? Only time. If it works out, we have estab-
lished an important legacy regarding our future
identity. If it doesn’t, we still will have clarified our
identity. If we fail in a genuine effort to make things
work within the ABS, we are in a vastly strengthened
position to proceed to full independence. Where
leadership is needed is in the exercising of sufficient
wisdom and judgment to recognize whether these
goals are achieved. But, it would also be leadership
failure if we were not to try this new relationship.
A broader identity issue involves the recognition
that others would usurp what we do and, in so
doing, trivialize nearly 100 years worth of experi-
ence beginning with, among others, the work of
Carrel. But this is a challenge to more than just sur-
gical technique or research; it challenges our role in
the care of patients with vascular disease. The iden-
tity crisis comes from the rapid emergence of less-
invasive technologies for vascular problems and the
progression of these technologies, which has hap-
pened so fast that most vascular surgeons don’t yet
possess sufficient skills to do them. The bigger prob-
lem is that others, interventional radiologists and
cardiologists, do possess sufficient skills. These tech-
nologies are based on fluoroscopy, guide wires, bal-
loons, stents, and the like, and most surgeons have
had scant experience, during training or since, with
these approaches and techniques. Let us consider
the problem: What do you suppose is going to hap-
pen as soon as endoluminal prosthetic devices are
“miniaturized” enough for percutaneous placement?
So, what do we do about this? First, we should
remember and then turn to our real strength to deal
with the situation. This strength is our full under-
standing of the problems of our patients, their natur-
al history, their interventions, and the results of what
is done for them. This is what we know best, the
right thing to do for a particular patient and when.
Most of us treat patients with mild-to-moderate
problems expectantly. We resist intervening just
because the lesion is there. With growing frequency,
this is not the case with others. For example, inci-
dental renal artery angioplasty for asymptomatic
stenosis is being performed increasingly by cardiolo-
gists during procedures on the coronary arteries. I
deplore these actions, because cardiologists don’t
really understand the consequences of their ques-
tionable initial treatment success. This does not
mean that this treatment strategy is globally wrong.
It does mean that this technology, as all new ones,
needs to be addressed carefully and studiously by
those who understand the problems in perspective—
those who already have a demonstrated responsibili-
ty for intervention and a compulsion about learning
the short- and long-term outcomes. This is the def-
inition of the vascular surgeon.
In contrast, endoluminal therapy for aortic
aneurysm is largely being evaluated by innovative
vascular surgeons. This is the right way, but if we
don’t sustain leadership over the evolution of all
such technology, all will suffer, in particular, our
patients. I said earlier that we are the guardians of
our patients’ welfare. We must maintain this respon-
sibility. If we fail this, we have failed in leadership,
and our legacy is dark. It is from this base that we
should proceed. So, what are the options? I offer 3.
First, we can do nothing. Let matters unfold as they
will. This is fundamentally unsound, because our
basis of practice will be eroded by others who don’t
understand the diseases we treat as well as we do.
Leadership boldness and leadership judgment, both
required in today’s instance, say that doing nothing
is simply not an option.
Second, we can form alliances with radiology,
cardiology, or both. In the past year, council repre-
sentatives have met with both groups. Vascular radi-
ologists already have developed and demonstrated
considerable skill in the less invasive therapies of vas-
cular lesions. Radiologists are also very concerned
about the future of their field. The discussions with
radiology are more advanced, because liaison there
has considerable logic. Cardiologists, in contrast,
seem less concerned, and some have declared that
peripheral arterial interventions are a part of cardiol-
ogy and, therefore, part of their turf. The problem
here is real. So, there is considerable impetus to form
“alliances” with both groups, for differing reasons,
to avoid very destructive “turf” wars. Joint ventures
in the form of centers exist today. A “hybrid” vascu-
lar interventionalist has been proposed, but how are
we going to do that? Can you envision a nonsurgeon
operating on someone now or anytime soon? On the
other hand, can you envision a vascular surgeon
doing all catheter-based interventions? I can.
Actually, there are some sitting in the audience who
already do this. To me, it is quite clear which way the
technology/skill transfer needs to go, but it won’t
go there unless we make it happen.
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The third option is just do it. Vascular radiolo-
gists have not been willing to teach vascular sur-
geons or our trainees catheter-based skills, but we
are learning them anyway. With some careful but
forceful leadership decisions, vascular surgeons in
training will become competent in these skills, there-
by ensuring that in the near future there may not be
a problem. However, in the meantime, we have a
large under served group in the middle—most of
this audience. We must develop training and educa-
tional opportunities for anyone interested in acquir-
ing these skills now. This will be tough to do. We
have a good start in several venues, including that
offered by the Joint Vascular Societies. But this is
only a start; we must do more.
I think we must approach this issue boldly and
broadly. As we train the residents and fellows to per-
form these innovative procedures, we must encour-
age them to do something heretofore difficult:
reverse the process. The young must teach the old.
For this to happen, the barriers, some practical,
some economic, and certainly some traditional, need
to be addressed. We should continue to explore
working arrangements with those in other fields
whom we know would usurp our identity, but see if
we can somehow enfold them within us. If so, fine,
but we can’t just keep talking with them indefinite-
ly. If we can’t, we must continue as we have in the
past and just do it. Learn it, do it, and teach it.
The lessons of history, observations of the pre-
sent, and goals for the future are an important amal-
gamation from which I hope we can gain insight
about how to proceed. Two years ago, our 50th
president, Frank Veith, likened the evolution of vas-
cular surgery to the observations of Charles Darwin
on the evolution of the species. It is true that we are
evolving, but we must be aggressively proactive in
what is now very rapid evolution. In Darwin’s terms,
we have to be the fittest if we are to survive. Legend,
leadership, legacy. We know the past, and we have
the leadership. Now we need to create our legacy.
Carpe diem.
I thank my wife, Cynthia, for her continued support
and my friend Suzanne Gautreau for her able assistance
and patience.
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